Andere talen Gan & Lee Pharmaceuticals.

Aandelen

603087

CNE100003ZH1

slotkoers Shanghai S.E. Andere beurzen 00:00:00 07-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
51,03 ^CNY	-1,54%		+1,98%	-3,08%

24/04	Gan & Lee Pharmaceuticals. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
24/04	Gan & Lee Pharmaceuticals. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	24/04
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	26/01
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	12/12
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	04/12
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding	10/11
Type 1 Diabetes Pipeline\| Clinical Trials and Key Companies - Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma	09/11
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	30-10-23
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval	12-10-23
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index	18-09-23
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index	18-09-23
Gan & Lee Pharma Advances Trial of New Insulin Product	13-09-23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	18-08-23
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	20-07-23
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	20-06-23
Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..	14-06-23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2023	27-04-23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2022	30-03-23
FDA Accepts Gan & Lee Pharma's Application for Insulin Glargine Injection	24-02-23
Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from S&P Global BMI Index	19-12-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Gan & Lee Pharmaceuticals.

Aandelen

603087

CNE100003ZH1

Andere talen

Filters